Insight on What Matters - So You Can Transform Your Business.
GlaxoSmithKline CEO Andrew Witty once commented on the high cost of drug development, saying, “If you stop failing so often, you massively reduce the cost of drug development.” So, why do clinical trials fail, and what can be done about it?
electing the right CRO to manage a clinical trial can be a critical decision in the program’s successful outcome. With so many CROs to choose from, what kind of evaluation criteria should be used?
On May 18-19, 2017 ExL Events will host the 4th Due Diligence Summit for Life Sciences at the Hyatt Regency in Boston. This is the only life sciences event that is focused on the needs of cross-functional due diligence professionals.
Cure SMA has their own series of molecules that they outlicense to potential partners to further treatment for SMA.
In light of our March 2017 web panel discussion, we sat down with Dr. Ravi Kiron, Managing Partner at Biopharm Strategy Advisors and moderator of the webinar, to find out whether this area could revolutionize the healthcare industry of the future or whether we are treading on dangerous ground that we know little about.
We recently had the opportunity to sit down with James C. Greenwood to get his perspective on the future of biopharma partnering.
According to Linda Pullan, PhD, of Pullan Consulting, partnering successfully requires knowing how to play the partnering game, starting with deciding when you should partner, then understanding the partnering process both from your perspective and the partner’s, clearly defining what it is you want from a deal and having an understanding of alternatives, and then reaching out to a variety of partners in order to find one that best fits your needs.
In an oncology world that is increasingly dominated by immuno-oncology therapies, we were curious to find out from Jeff if non immuno-oncology therapies will maintain a role in oncology's future.
In 2016, the biopharmaceutical industry raised $37.3B compared with $37B in 2014. 2016 falls only slightly behind what many consider the industry’s blockbuster year of 2000, which raised $38B.
Successful BioPharma partnerships don’t happen by chance, and negotiating an out-licensing deal can be complex— especially when the company is also focusing on progressing the clinical portfolio.
Blog